Visa enkel post

dc.contributor.authorWittfeldt, Ann
dc.date.accessioned2016-11-17T12:23:29Z
dc.date.available2016-11-17T12:23:29Z
dc.date.issued2016-11-17
dc.identifier.isbn978-91-628-9996-7 (print)
dc.identifier.isbn978-91-628-9995-0 (pdf)
dc.identifier.urihttp://hdl.handle.net/2077/44868
dc.description.abstractBACKGROUND AND OBJECTIVES Coronary flow velocity (CFV) and coronary flow velocity reserve (CFVR) evaluated by transthoracic ultrasound is a promising method to assess ischemic heart disease. CFVR is the ratio between CFV during maximal hyperemia and baseline. A reduced CFVR indicates an increased risk for cardiovascular events. The aims of this thesis were 1. To evaluate the effect of nitroglycerine administration on CFV and CFVR. 2. To investigate if CFVR provides prognostic information about cardiovascular events, in addition to myocardial scintigraphy, in patients with suspected coronary artery disease. 3. To investigate the relationship between CFVR and significant coronary stenosis. 4. To assess the effects of ticagrelor on CFV and dyspnea. METHODS In study I, CFV and CFVR and coronary artery diameter were assessed before and after sublingual nitroglycerine administration in 26 healthy subjects. In study II, CFVR was measured in 371 patients undergoing scintigraphy due to suspected coronary artery disease. CFVR and scintigraphy results were related to cardiovascular events (cardiovascular death, myocardial infarction, acute revascularization) during a mean follow-up of 4.5 years. In study III, CFVR and coronary angiograms were evaluated in 123 patients from study II (n=123). Study IV was a double-blind placebo-controlled cross-over study randomizing 40 healthy subjects to ticagrelor or placebo. CFV and dyspnea were assessed at baseline and during increasing doses of adenosine. RESULTS Nitroglycerine increased CFVR due to a reduction in baseline CFV. Adenosineinduced CFV remained unchanged. A CFVR≤2 was independently associated with cardiovascular event rate (adjusted hazard ratio 3.02 (1.51-6.04, p=0.002) and added prognostic information in addition to scintigraphy. There was a significant association between CFVR and the presence of coronary stenoses. Ticagrelor augmented CFV and dyspnea during adenosine administration. CONCLUSIONS Nitroglycerine increases CFVR which indicates that adenosine alone causes a submaximal hyperemia. The associations between CFVR and cardiovascular events, and between CFVR and significant coronary stenosis supports routine assessment with CFVR in patients with suspected ischemic heart disease. The results indicate that adenosine is involved in the systemic effects of ticagrelor. Keywords: ischemic heart disease, coronary flow velocity, ultrasoundsv
dc.language.isoengsv
dc.relation.haspartWittfeldt A, Jeppsson A, Gan LM. Effects of nitroglycerine on coronary flow velocity before and during adenosine provocation. Submitted.sv
dc.relation.haspartGan LM, Svedlund S, Wittfeldt A, Eklund C, Gao S, Matejka G, Albertsson P, Omerovic E, Lerman A. Incremental value of transthoracic Doppler echocardiography-assessed coronary flow reserve in patients with suspected myocardial ischemia undergoing myocardial perfusion scintigraphy. Submitted.sv
dc.relation.haspartHaraldsson I, Gan LM, Svedlund S, Wittfeldt A, Råmunddal T, Angerås O, Albertsson P, Matejka G, Omerovic E. Non-invasive evaluation of coronary flow reserve with transthoracic Doppler echocardiography predicts the presence of significant stenosis in coronary arteries. Int J Cardiol. 2014 Sep;176(1):294-7. ::DOI::10.1016/j.ijcard.2014.06.076sv
dc.relation.haspartWittfeldt A, Emanuelsson H, Brandrup-Wognsen G, van Giezen JJ, Jonasson J, Nylander S, Gan LM. Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans. J Am Coll Cardiol. 2013 Feb 19;61(7):723-7. ::DOI::10.1016/j.jacc.2012.11.032sv
dc.subjectcoronary flow velocitysv
dc.subjectischemic heart diseasesv
dc.subjectultrasoundsv
dc.titleNon-invasive assessement of coronary flow velocity: Clinical and experimental studiessv
dc.typetexteng
dc.type.svepDoctoral thesiseng
dc.gup.mailann.wittfeldt@gu.sesv
dc.type.degreeDoctor of Philosophy (Medicine)sv
dc.gup.originUniversity of Gothenburg. Sahlgrenska Academysv
dc.gup.departmentInstitute of Medicine. Department of Molecular and Clinical Medicinesv
dc.gup.defenceplaceOnsdagen den 7 december 2016, kl 13.00, Hjärtats aula, Vita stråket 12, Sahlgrenska sjukhuset, Göteborgsv
dc.gup.defencedate2016-12-07
dc.gup.dissdb-fakultetSA


Filer under denna titel

Thumbnail
Thumbnail

Dokumentet tillhör följande samling(ar)

Visa enkel post